Skip to main content

BT-474: Human Mammary Invasive Ductal Carcinoma

BT-474
BT-474
ParameterInformation
StrainNSG
Implant TypeCells
Implant LocationSC, Axilla
Time to Staging7 days
Time to Evaluation Size 750mm³35 days
Td14.8 days

The above parameters are from one study. For further information on this cell line and other parameters, including different strains, vendors, implant type and location and/or standards of care, please contact us.

Histotype

Mammary/Breast

Tumor Line

Human

Ref #

3846

Spotlight on BT-474 Human ductal breast carcinoma

Learn more about this cell line in our scientific spotlights:

The BT-474 cell line has a long history, but many of us thought it had run its natural course and was quickly becoming obsolete. The American Type Culture Collection (ATCC) reports that the BT-474 cell line was originally established in 1978 by E. Y. Lasfargues, who obtained a tumor biopsy from a 60-year-old woman with advanced stage invasive ductal breast carcinoma. The cell line was later classified as estrogen receptor positive (ER), progesterone receptor positive (PR) and human epidermal growth factor receptor 2 positive (HER2) (1). This information was critical in linking the BT-474 model used in preclinical breast cancer research to real patients with the same genetic profile.

Please note that cell lines are not for sale and are unavailable for purchase.

Get started setting up your next preclinical study